Pulmonary Circulation · 2018 · 15 citations · 18 references
MedicineCardiologyPhysiologyClinical CardiologyPulmonary Function TestingPulmonologyEchocardiographic Hemodynamic AssessmentHeart FailurePulmonary Artery CatheterizationPulmonary Function AssessmentPulmonary HypertensionPulmonary Vascular DiseaseCardiac Catheterization FindingsInhaled Nitric Oxide TherapyPulmonary HemodynamicsPulmonary Venous HypertensionRight Ventricular EchocardiographyRight Ventricular HemodynamicsRight Ventricular Systolic FunctionTwo-dimensional Echocardiography
Pulmonary vein stenosis (PVS) is associated with pulmonary hypertension (PH), but there is little information regarding the impact of PH on right ventricular (RV) systolic function and survival. We conducted a retrospective cohort study of our patients to explore this and other aspects of pulmonary hemodynamics with PVS. RV function was assessed using qualitative two‐dimensional echocardiography. The ratio of systolic pulmonary artery (PA) and aortic pressures (PA:Ao) at cardiac catheterization reflected pulmonary hemodynamics. Reactivity testing employed inhaled nitric oxide + 100% fiO 2 , or 100% fiO 2 only; “reactivity” was a ≥ 20% decrease in PA:Ao. There were 105 PVS patients, although not all had data at every time point. (1) The mean PA:Ao at first cardiac catheterization (n = 77) was 0.79 ± 0.36; at last catheterization (n = 54), PA:Ao = 0.69 ± 0.30; 90% had systolic PAP > one‐half systemic. Survival was shorter with PA:Ao > 0.5. (2) Differences in survival relative to RV dysfunction on the first echocardiogram were not significant, although they were using the last echocardiogram. (3) The magnitude of RV dysfunction was positively correlated with PA:Ao. (4) Balloon dilation of PV acutely decreased PA:Ao (–0.13 ± 0.37, P = 0.03 [n = 40 patients]). 5. Of 20 patients tested, 13 were acutely reactive to vasodilators. PH is a major feature of PVS. Reduced RV function and PA:Ao appear to be predictors of survival. Given the importance of PH in this disease, clinical studies of PVS treatments should include measures of PAP and RV function as important variables of interest.
18
Pediatric Pulmonary Hypertension
Steven H. Abman, Georg Hansmann, Stephen L. Archer et al. · Circulation · 2015 · 1.1K citations · Full text
Medicine, Cardiology, Pediatrics +8
Renée Margossian, Marcy L. Schwartz, Ashwin Prakash et al. · The American Journal of Cardiology · 2009 · 224 citations
Medicine, Cardiology, Pediatrics +17